Core Viewpoint - Bausch + Lomb Corporation will participate in the 44th Annual J.P. Morgan Healthcare Conference, highlighting its commitment to eye health and innovation [1]. Group 1: Company Presentation - The presentation will feature Chairman and CEO Brent Saunders, Executive Vice President and CFO Sam Eldessouky, and Chief Medical Officer Yehia Hashad, MD [1]. - The event is scheduled for January 12, 2026, at 1:30 p.m. PT (4:30 p.m. ET) [1]. Group 2: Investor Relations - A live webcast and audio archive of the event will be accessible on the Investor Relations page of the Bausch + Lomb website [2]. Group 3: Company Overview - Bausch + Lomb has a mission to help people see better to live better, with a history of nearly two centuries in evolving to meet patient and customer needs [3]. - The company focuses on innovation and improving standards of care in eye health, offering a range of products from contact lenses to surgical devices [3].

Core Viewpoint - Bausch + Lomb Corporation is refinancing its outstanding term B loans with a new tranche of Replacement Term Loans amounting to $2,802,125,000, aimed at extending maturity and reducing interest rates on existing loans [1]. Financial Summary - The Replacement Term Loans will refinance all outstanding term B loans due in 2031 and 2028, with a maturity date of January 15, 2031, which extends the maturity of the First Incremental Term Loans from September 29, 2028 [1]. - The applicable margin for the Replacement Term Loans is set at 3.75% per annum for loans referenced to term SOFR and 2.75% per annum for loans referenced to the alternate base rate, representing a reduction of 0.50% and 0.25% per annum for the respective loans [1]. Transaction Timeline - The transactions related to the Replacement Term Loans are expected to close in the first quarter of 2026, although there are no guarantees that they will be completed as planned [2]. Company Overview - Bausch + Lomb has a long-standing mission to enhance eye health and improve the quality of life for individuals globally, with a diverse product range including contact lenses, prescription products, and surgical devices [3].

Company Overview - Pro-Dex, Inc. (PDEX) is a contract manufacturer focused on designing, developing, and manufacturing surgical devices for the medical device industry [1] - The stock has experienced significant volatility over the past year, trading between a high of $70 and a low of $16 [1] Performance Insights - The company has achieved record performance, although specific metrics or figures are not provided in the text [1]